Aim: To investigate 10-year outcomes of high-dose image-guided intensity-modulated radiation therapy (IG-IMRT) combined with long-term androgen deprivation therapy (ADT) for Japanese patients with nonmetastatic prostate cancer.
populations with the lowest incidence and mortality. When patients with nonmetastatic prostate cancer undergo radiotherapy (RT), the combination of long-term androgen deprivation therapy (ADT) is recommended in the NCCN guidelines, particularly for patients with high-risk and very-high-risk disease. 9, 10 When patients with non-metastatic prostate cancer choose RT among several treatment options, image-guided intensity-modulated RT (IG-IMRT) is the most promising technique for the safe delivery to the target volume and the dose reductions to normal tissues. 11, 12 As for high-dose IG-IMRT combined with long-term ADT, few reports have shown the oncologic outcomes with mature follow-up worldwide as well as in Asia. Thus, we examined 10-year outcomes of IG-IMRT with long-term ADT for Japanese patients with localized or locally advanced prostate cancer, to compare our outcomes with those in other countries.
METHODS

Patient selection and pretreatment assessment
This study was approved by our Institutional Review Board. Informed consent was obtained before treatment. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The inclusion criteria of this retrospective study were as follows: histologically confirmed prostatic adenocarcinoma; clinically localized or locally advanced prostate cancer; definitive IG-IMRT operations at our institution from 2006 to 2010. Exclusion criteria were as follows: lymph node (LN) metastasis or distant metastasis on imaging tests; lost follow-up before 5 years passed after IG-IMRT. The pretreatment assessments included complete medical history and physical examination, laboratory evaluation, serum prostate-specific antigen (PSA), digital rectal examination, computed tomography (CT) of the chest, abdomen, and pelvis, magnetic resonance imaging of the pelvis, and bone scintigraphy. A risk stratification followed the NCCN guidelines version 2.2018. 9 Patients with T3b-T4 or primary Gleason pattern 5 or cores > 4 with Gleason score 8-10 were classified into the very-high-risk group.
Radiotherapy and hormonal therapy
All patients were immobilized with the Esform vacuum type immobilization system (Engineering System, Matsumoto, Japan). All patients defecated when possible every morning and discharged urine about 1 h before CT simulation and IMRT to minimize daily variations in the shape and anatomical location of the prostate. IG-IMRT was adminis- Patients underwent salvage ADT after biochemical relapse. Details of IG-IMRT and ADT methods were managed in the same manner as in the study. 13 
Statistical analysis
Follow-up was performed at an interval of 3 months. When PSA values were kept at a low level after 3-5 years, the follow-up interval was extended to every 4-6 months. Serum PSA and toxicity was checked at each follow-up. The primary objective was to examine biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS), prostate cancer-specific survival (CSS), and overall survival (OS) of IG-IMRT combined with long-term ADT for Japanese patients with nonmetastatic prostate cancer. The secondary objective was to examine toxicities for Japanese patients with nonmetastatic prostate cancer. A biochemical relapse was defined as a posttreatment nadir plus 2.0 ng/ml of PSA. 14 Therapy Oncology Group morbidity grading scale. 15 All statistical analyses were performed using EZR (version 1.37), 16 which is a graphical user interface for R (version 3.4.1; R Foundation for Statistical Computing, Vienna, Austria). A P value of <0.05 was defined as significance.
RESULTS
Patient and treatment characteristics
No biochemical or clinical relapse was observed till the last day of follow-up in patients lost to follow-up. One patient died of other cancers before 5 years passed after IG-IMRT, who was included in this study. The final cohort consisted of 208 Japanese patients. 
Outcomes
The rates of 10-year bDFS, cRFS, CSS, and OS in all the groups were 82% (95% confidence interval [CI], 73-89%), 92% (95% CI, 84-96%), 95% (95% CI, 87-98%), and 91% (95% CI, 83-95%), respectively. Table 2 shows the summary of outcomes. Figure 1A and 1B shows bDFS and cRFS in each risk group. The 10-year bDFS rates for low-, intermediate-,
high-, and very-high-risk group patients were 100%, 84% (95% CI, 54-95%), 90% (95% CI, 70-97%), and 72% (95% CI, 57-83%), respectively (P = 0.008). The 10-year cRFS rates were 100% for low-, intermediate-, 
Toxicity
Late gastrointestinal (GI) and genitourinary (GU) toxicities of grade 2 or higher occurred in 24 patients (12%) and 27 patients (13%),
respectively. Late GI toxicities of grade 2 and grade 3 were observed in 20 patients (10%) and four patients (2%), respectively. Late GU toxicities of grade 2 and grade 3 were observed in 24 patients (12%) and three patients (1%), respectively. No grade 4 or 5 late GI or GU toxicity was observed. The 10-year cumulative incidence of late grade 2 or higher GI and GU toxicities was 12% (95% CI, 7-16%) and 13%
(95% CI, 8-18%), respectively. In 11 patients (5%), 12 cardiovascular bDFS, biochemical disease-free survival; cRFS, clinical relapse-free survival; CSS, caner-specific survival; OS, overall survival. Data are n or % (95% confidence interval).
events developed: eight patients (4%) with a coronary disease and four (2%) with a cerebrovascular disease. However, no fatal events occurred in these patients.
DISCUSSION
The results of this retrospective study showed that high-dose IG-IMRT combined with long-term ADT provided excellent 10-year bDFS, cRFS, CSS, and OS for Japanese patients with nonmetastatic prostate cancer.
The comparisons of our long-term outcomes with other clinical outcomes are summarized in Table 4 . [17] [18] [19] [20] [21] [22] Our favorable outcomes could be associated with three main factors; high-dose IG-IMRT, combination with long-term ADT, and race difference.
First, high-dose IG-IMRT with adequate target coverage and accurate setup could contribute to these favorable outcomes. These techniques permit safer dose escalation 12 and improve clinical outcomes substantially with high-dose RT in patients with nonmetastatic prostate cancer. 23, 24 Dose escalations could result in significant improvements of biochemical control, even when used in combination with long-term ADT. 25 The second factor of our favorable outcomes was the combination of long-term ADT. We have combined long-term ADT with RT for patients with nonmetastatic prostate cancer because a metaanalysis of randomized trials showed the merit of long-term ADT with conventional-dose RT for patients with intermediate-and high-risk disease. [26] [27] [28] Now, the effect of long-term ADT is verified in patients who received even high-dose RT, particularly in men with high-risk disease. 10 As for the high-risk disease, the 10-year bDFS rates were 56-68% as shown in Table 4 . [17] [18] [19] [20] [21] Thus, our bDFS rate (90%) was superior to these bDFS rates of other studies with or without short-term showed that shorter duration of ADT (< 24 months) tended to be associated with biochemical relapse (HR, 1.7; 95% CI, 0.56-5.5; P = 0.34), as shown in Table 3 . The result of an additional analysis for only the high-and very-high-risk groups also did not show any difference in outcomes with the ADT duration (< 36 months vs ≥ 36 months). Perhaps, this may be due primarily to the use of long-term ADT in most patients and/or a small sample size. In addition, we consider whether ADT times can be potentially shortened for Japanese high-risk group patients in terms of race difference between Japanese and Caucasians or African
Americans. The very-high-risk classification requires the identification of those for whom it is needed to reconsider the optimal therapeutic strategy. 29, 30 The outcomes of the very-high-risk group were obviously inferior to those of the remaining risk groups in this current study.
Thus, not only long-term ADT but also systemic agents may be necessary as the treatment strategy in the very-high-risk group of Japanese patients, as well as patients of other countries such as Europe and America. 31 On the other hand, we recognize that the ADT duration can be shortened in Japanese patients not only with low-risk disease, but also with intermediate-risk disease. As for the intermediate-risk disease, the 10-year bDFS rates shown in Table 4 17-21 were 78-87% and these bDFS rates were equivalent to our bDFS rate (84%) in spite Table 4 . Racial disparities observed in prostate cancer patients may be a consequence of genetic predisposition and epigenetic events, both of which involve environmental risk factors. 5, 6 Kimura reported about ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. 7 The Asian immigrants in the western countries had higher incidence of prostate cancer compared to those in their countries of birth. 32 It might be because of the different medical systems and diet. Soy foods are popular among Asian countries and are reported to be associated with a 25-30% reduced risk of prostate cancer. 33, 34 The family history is one of the established risk factors for prostate cancer, 32 and their genetic predispositions and/or environmental factors should be involved in its etiology. An individual with a positive family history has a 23-time higher risk of the incidence of prostate cancer. 35, 36 The Inter- Whites and Japanese men and found evidence of lower testosterone metabolism in the Japanese men. 44 The incidence of late grade ≥2 GU and GI toxicity reportedly ranges from 13% to 40% and from 26% to 30%, respectively, in high-dose (78 Gy) RT arms of recent studies. [45] [46] [47] In this current report at the high-dose level of IG-IMRT, the risks of developing late grade ≥2 GI and GU toxicities were 12% and 13%, respectively, at 10 years. Taken
together, these data demonstrate that IG-IMRT is the most promising technique in the dose reductions to the normal tissues. 11, 12 This single institutional retrospective study had some limitations. Perfect grading and accurate evaluation of toxicity were not expectable because this study is retrospective. The low rate of cardiovascular events in our current study (5%) might be associated with the lower incidence of ischemic cardiac disease in Japan than in Europe or USA. 48 However, the results of randomized controlled trials did not show an increase in the incidence of cardiovascular mortality from ADT with 8-10 years follow-up, nor did the data from a meta-analysis. 49, 50 Further limitations include a few variety of assessments and treatments because of the retrospective study, for example, pretreatment assessments such as the number of biopsies and ADT times in each risk group. In addition, although we think that races might be associated with our favorable outcomes, we did not make a direct comparison of outcomes between our Japanese patients and Caucasian or African bDFS, biochemical disease-free survival; cRFS, clinical relapse-free survival; CSS, caner-specific survival; HDR-BT, high-dose rate brachytherapy; IMRT, intensity modulated radiation therapy; 3DRT, three-dimensional radiation therapy; CIRT, carbon-ion radiotherapy; ADT, androgen deprivation therapy; NA, not applicable, IG, image guided. a 97 of 608 patients experienced biochemical relapse.
CONCLUSION
The results of this report indicate that IG-IMRT combined with longterm ADT is associated with the favorable 10-year outcomes with acceptable late toxicities for Japanese patients with nonmetastatic prostate cancer. The outcomes of the very-high-risk group were apparently inferior to the outcomes of the remaining groups, so that for the very-high-risk group, the development of new combination therapies with high-dose IG-IMRT is essential. The combination with long-term ADT was effective, but an appropriate ADT duration may necessarily be examined for East Asian populations.
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